Iovance Biotherapeutics Stock Analysis

Stocks for Iovance Biotherapeutics (NASDAQ: IOVA) have seen a dramatic 75% drop since reaching their peak in December last year. Investment analysts across various banks are focused on tracking companies that are developing cancer therapies.

At Chardan Capital, analyst Geulah Livshits maintains a purchase rating with a price target of $25 as of July 23. Considering the stock price of $3.05 on July 28, that estimate suggests a potential profit of about 720% over the course of a year.

Not all investment banks share Chardan’s enthusiasm for Iovance, though expectations remain high overall. When the market opened on July 28, the consensus price target was set at $10 per share.

With an average price target suggesting a 228% profit, it’s clear that expectations for the company have significantly evolved. It’s important to weigh the strengths of Iovance against the various challenges it faces to determine if it’s a good time to consider buying the stock.

In February 2024, the FDA gave the green light to Iovance’s first product, Amtagvi, designed as a cell-based therapy for patients with progressive melanoma. This treatment involves isolating and expanding immune cells, specifically tumor-infiltrating lymphocytes, which then work to attack the tumor after being reintroduced into the body.

Current standard care for melanoma usually includes PD-1 blocking antibodies like Merck’s Keytruda, but options are limited if these treatments fail. In trials leading up to the approval, AMTAGVI showed a reduction in tumors for 31.5% of patients who had already undergone PD-1 therapies.

Since gaining approval, Iovance has treated 41 patients, with 20 showing small tumors or no tumors at all. Among those who had previously only received one or two lines of treatment, the response rate climbed to 60.9%.

However, on July 15, Goldman Sachs downgraded the stock and reduced their price target to $1 per share, raising concerns about the slower-than-anticipated launch of Amtagvi.

Amtagvi’s rollout faces several challenges. The FDA approved it based solely on tumor reduction rather than overall survival benefits, which are harder to assess. Additionally, Iovance’s sales team is quite small, with around 838 employees, of which only 670 are involved in research, development, and manufacturing.

Moreover, the administration of Amtagvi is complex. Unlike a simple pill refill, it involves injecting live immune cells. To ensure these new cells can find a place in the patient’s bone marrow, treatment centers must first deplete the immune system with a week-long chemotherapy regimen.

These obstacles contributed to AMTAGVI sales of $43.6 million in the first quarter of 2025. While not terrible, this figure does not align with initial expectations of blockbuster success.

Iovance’s current stock price is at a 52-week low, with a market capitalization of approximately $1.05 billion. This is relatively low compared to other drugmakers whose products operate similarly to Amtagvi. Management aims for sales between $250 million and $300 million this year, but biotechnology companies typically have medium to high trading multiples based on 12-month sales.

Should Goldman Sachs’ assessment be inaccurate and Iovance meets earlier earnings projections, the stock could potentially surge. Iovance may indeed be undervalued, but it might be wise to wait for the upcoming second quarter results, due on August 7.

In June, the resignation of Iovance’s chief financial officer was announced. It’s not uncommon for CFO changes to occur as drug startups approach key product launches, and this resignation, after more than a year, gives some hope that new leadership could help improve their disappointing sales guidance.

If Amtagvi manages to meet Wall Street’s expectations, the outlook could drastically change, but it’s probably best to hold off until the second quarter report is released.

Potential investors should think carefully before considering Iovance Biotherapeutics stock.

Some analysts at Motley Fool Stock Advisor have identified their top choices for investment, and interestingly, Iovance wasn’t included among them. The selections that made the list could potentially offer significant returns in the coming years.